2022
Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis
Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology 2022, 76: 1862-1879. PMID: 35611859, PMCID: PMC9796683, DOI: 10.1002/hep.32591.Peer-Reviewed Original ResearchMeSH KeywordsAzathioprineBiomarkersHepatitis, AutoimmuneHumansImmunosuppressive AgentsLiver CirrhosisQuality of LifeConceptsAutoimmune hepatitisNormal serum transaminasesPediatric autoimmune hepatitisFirst-line treatmentAcute liver failureImmune cell phenotypesPredictors of responseHigh clinical valueNovel candidate biomarkersPersonalized therapeutic managementSystemic corticosteroidsCurrent regimensMedication titrationHistological activityMost patientsClinical courseLiver failureLiver injurySerum transaminasesMedication dosingTherapeutic managementUnclear etiologyHepatic fibrosisClinical valueElevated risk
2020
Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting American Association for the Study of Liver Diseases Guidelines
Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis D, Manns MP, Mayo MJ, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology 2020, 72: 753-769. PMID: 32500593, DOI: 10.1002/hep.31407.Peer-Reviewed Original Research
2011
Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation
Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.Peer-Reviewed Case Reports and Technical NotesConceptsLiver allograft rejectionHepatitis C virusRenal graft rejectionAllograft rejectionHCV recurrenceCholestatic hepatitisGraft rejectionHCV RNAPatient survivalEnd-stage liver disease (MELD) scoreOne-year patient survivalIFN/RBV therapyFIBROSING CHOLESTATIC HEPATITISHistologic HCV recurrenceIFN/ribavirinOne-year graftSuccessful salvage strategiesTime of OLTHCV RNA levelsLiver Disease scoreAnti-HCV therapyCohort of patientsEarly graft failureFCH groupOLT recipients